London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I will chew my toenails if that’s the case
Any guestimates on worst case/best case dividend x pence for Haleon? Right now 0 as its all subject to performance but like to see what it might be if its in line with expectations from the pre-split conjuring..
Just to make sure when I say covered I don’t mean eradicating the whole debit. I’m talking about comfortably cutting into the debit whilst still paying a div. :-)
Hi Gerry,
The debit is not a problem and will be easily covered over the next five or so years by part of the profits they will make on their products. They can also cut the div a bit if they want to knock it down a bit. Which I would not complain about. Haleon is a massive personal healthcare company now and will only get bigger . In regard to the debit I think that’s why the majority was put on to Haleon. Also I would not be surprised if a very large American healthcare company made a move for Heleon as the figures and future look bright indeed. :-).
Some goods are just not price sensitive - they have low price elasticity - i.e. when the price goes up, although some customers will drop of, the rise in price will more than compensate for those few lost sales.
I'd include all healthcare products in that - people feel that they are a necessity, and that they are getting a better product with a brand, where as in reality they are all virtually the same.
We don't take so many chances with our healthcare.
Personally, I'm not a slave to any brand, but I do choose branded toothpaste at 4 times the price of supermarket own, when I know in reality there is no difference. Can't think of another product where I think like that
Hi Seaking1, would you care to share on your thoughts and or reasons why.
Debt levels, low yield and overly confident growth predictions are my cons.
As for pros, takeover or buyout potential maybe and Dave Lewis. I'm holding the free ones currently and sat on the fence
Extremely strong buy in my view. Any of my other shares go blue on my buy price will be sold and money put in here.
Surely this has always been the case. It's all in the marketing.
I know I'm a VERY disloyal shareholder when it comes to painkillers, always the generics for pennies.
Only thing I do get is sensodyne...
Is there a danger that the general public will switch from Panadol and Sensodyne to more generic paracetamol and cheaper sensitive toothpastes as the cost of living bites? I can purchase paracetamol generic for much less than the brand name.....in the Netherlands in May, I was able to purchase double the amount of paracetamol for the same price as back home........does Haleon produce any generic brands?
Denby, your inquiry has been answered by all at sea. You hear the headlines from the gov squawk on about inflation, but in truth they are reasonably happy as it brings down the country’s debit. :-).
Inflation reduces debt liability.
What makes you think that likes of Unilever announced they would buy Haleon now WHEN INFLATION is starting to rise seeing their debt?
Apologies if this has been covered before but does anyone have an idea of how many dividends with this new company we will receive year ? Also when the first one is likely ? many thanks sam
Looking to get back in to Haleon having sold my GSK at 1780 before split/consolidation. At their current price of about €3.08....is this not already looking attractive for a predator at that price. If all shares were picked up, plus debt.....would the price come in at well below €50 billion.
What about PlutHygieia?
At least it would indicate some wish for the company to be successful.
(Sharecast News) - Credit Suisse has initiated coverage of Haleon, GlaxoSmithKline's recently spun out consumer healthcare arm, at 'outperform' with a 368p price target.
The bank said Haleon is a "highly attractive" company. It said that as the only listed pure-play in Consumer Health - an industry with structural growth trends - Haleon's current valuation fails to recognise the company's scope to deliver above-guidance organic sales growth of 6.5% in FY22, followed by 4.5% in FY23.
It also fails to recognise the improved portfolio of the business (post recent M&A and divestments) and its ability to leverage scale as the clear global leader, with a market share twice that of its nearest competitor.
Credit Suisse said that based on its analysis of more than 100 country/category cell forecasts, it expects Haleon to deliver 4.2% organic sales growth per annum over the medium term, which reflects around 10 basis points a year market-share expansion.
CS said Haleon has high-quality earnings growth potential of circa 7.5% per year, benefitting from further margin expansion and reduced interest cost.
"Compared to consumer staples, the company has a relatively low exposure to input costs (less than 10% of sales) and emerging market currencies, and is likely more resilient in an economic downturn, in our view," it said.
It added that the step-up in cash conversion should allow the group to de-lever quickly.
Price on the up today....have all the early sellers sold up and moved on?....hopefully see it settle down to broadly follow the market until 1st results...
Eccles - you are clearly taking the P155. I don't care how you acquired your shares - with over 4000 posts you are clearly doing some reading.
So many negative articles out there about Haleon. I am willing to wait until the dust settles on this and see where it goes.
If you could manage my account I would be very pleased as I don't make any money hope you can make money for me. So why have we got these shares under another account.
Hi Eccles, This basically represents the balance from the consolidation of the GSK shares ie 20% of your previous holding prior to the value from the end of last week.
Thanks for s answer my question why have they gone under a different name as I still have GKS can somebody tell me what's going on here please
oh no! Gave myself away as a scammer by use of bad English and spelling mistakes :)
FFS
Eccles - would you like me to manage you portfolio for you?
Just post your account details & password here and leave the rest to me.
I suggest you do a bit of research